Aripiprazole - Revision history

MDElliottMD: home-claude house-rule fix (terminology)

2026-05-23T10:40:58Z

home-claude house-rule fix (terminology)

← Older revision		Revision as of 10:40, 23 May 2026
Line 10:		Line 10:
	\| pill_id =		\| pill_id =
	\| routes = Oral, intramuscular (acute and long-acting)		\| routes = Oral, intramuscular (acute and long-acting)
	\| onset = ~~Antipsychotic~~ effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days		\| onset = Neuroleptic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days
	\| duration = 24 hours (oral); 4-8 weeks (LAI)		\| duration = 24 hours (oral); 4-8 weeks (LAI)
	\| halflife = ~75 hours (long, accumulates over weeks)<ref name="abilify-label">FDA Prescribing Information, Abilify (aripiprazole), Otsuka/Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf</ref>		\| halflife = ~75 hours (long, accumulates over weeks)<ref name="abilify-label">FDA Prescribing Information, Abilify (aripiprazole), Otsuka/Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf</ref>

MDElliottMD: parser-claude: Aripiprazole MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:54:25Z

parser-claude: Aripiprazole MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:54, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Aripiprazole		\| generic = Aripiprazole
	\| brand = Abilify		\| brand = Abilify (oral), Abilify Maintena (monthly IM LAI), Aristada (aripiprazole lauroxil IM LAI), Abilify Asimtufii (bi-monthly IM LAI), Abilify MyCite (digital ingestion sensor)
	\| structure =		\| structure =
	\| classes = ~~Antipsychotic~~, ~~Neuroleptic~~		\| classes = [[:Category:Neuroleptics\|Neuroleptic]], [[:Category:Atypical neuroleptics\|Atypical neuroleptic]], [[:Category:Third-generation neuroleptics\|Third-generation neuroleptic]], [[:Category:Mood stabilizers\|Mood stabilizer]]
	\| ~~mechanism~~ = D2/~~D3 partial agonist; 5~~-~~HT1A partial agonist; 5~~-~~HT2A antagonist~~		\| uses = <vote slug="schizophrenia-use">Schizophrenia (FDA, ages 13+)</vote>, <vote slug="bipolar-mania-mixed-use">Bipolar mania and mixed episodes (FDA)</vote>, <vote slug="bipolar-maintenance-use">Bipolar maintenance (FDA)</vote>, <vote slug="mdd-adjunct-use">Major depressive disorder adjunct (FDA)</vote>, <vote slug="autism-irritability-use">Autism spectrum disorder-associated irritability (FDA, pediatric ages 6-17)</vote>, <vote slug="tourette-syndrome-pediatric-use">Tourette syndrome (FDA, pediatric)</vote>
	\| ~~uses~~ =		\| starting_dose = Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap
	\| ~~starting_dose~~ =		\| preparations = Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly
	\| ~~preparations~~ =		\| fda_max = 30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct)
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral, intramuscular (acute and long-acting)
	\| onset =		\| onset = Antipsychotic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days
	\| duration =		\| duration = 24 hours (oral); 4-8 weeks (LAI)
	\| halflife =		\| halflife = ~75 hours (long, accumulates over weeks)<ref name="abilify-label">FDA Prescribing Information, Abilify (aripiprazole), Otsuka/Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~87% (oral)<ref name="abilify-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data; signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly patients with dementia-related psychosis, and the antidepressant suicidality '''Boxed Warning''' when used for MDD adjunct in patients under 24<ref name="abilify-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="aripiprazole-mech-claim">'''D2 and D3 dopamine receptor partial agonist''' (the third-generation neuroleptic signature, distinct from olanzapine/risperidone full D2 antagonism), with additional 5-HT1A partial agonism and 5-HT2A receptor antagonism. The D2 partial agonism is the "dopamine system stabilizer" rationale: in hyperdopaminergic states (psychosis, mania) aripiprazole functions as a partial antagonist; in hypodopaminergic states (prefrontal cortex, MDD adjunct) it functions as a partial agonist.</vote> '''Akathisia''' is the most common dose-limiting adverse effect, particularly with the MDD-adjunct dose range. Lower weight gain, lower metabolic burden, and lower prolactin elevation than most second-generation neuroleptics, the principal pharmacological selling points. CYP2D6 and CYP3A4 metabolism; CPIC PGx guidance applies for CYP2D6 dose individualization<ref name="abilify-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	~~[[Category:Second-generation neuroleptics]]~~		== References ==
			<references />

	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
			[[Category:Atypical neuroleptics]]
	[[Category:Third-generation neuroleptics]]		[[Category:Third-generation neuroleptics]]
			[[Category:Mood stabilizers]]

MDElliottMD: Category taxonomy (#23): retag to house-compliant neuroleptic categories

2026-05-22T14:41:17Z

Category taxonomy (#23): retag to house-compliant neuroleptic categories

← Older revision		Revision as of 14:41, 22 May 2026
Line 31:		Line 31:
	}}		}}

	[[Category:Second-~~Generation Antipsychotics (SGAs / Atypicals)~~]]		[[Category:Second-generation neuroleptics]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
	[[Category:Third-~~Generation Antipsychotics~~]]		[[Category:Third-generation neuroleptics]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged.

2026-05-19T18:00:16Z

Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 31:		Line 31:
	}}		}}


	~~[[Category:Antipsychotics / Neuroleptics]]~~
	[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]		[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
	[[Category:Third-Generation Antipsychotics]]		[[Category:Third-Generation Antipsychotics]]

MDElliottMD: Comprehensive categorization: +Third-Generation Antipsychotics

2026-05-15T18:42:09Z

Comprehensive categorization: +Third-Generation Antipsychotics

← Older revision		Revision as of 18:42, 15 May 2026
Line 35:		Line 35:
	[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]		[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]
			[[Category:Third-Generation Antipsychotics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:50Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Antipsychotics / Neuroleptics]]
			[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:42Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:24Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:39Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Neuroleptics]]		[[Category:Neuroleptics]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Aripiprazole
+| generic            = Aripiprazole
-| brand             = Abilify
+| brand              = Abilify
-| classes           = Antipsychotic, Neuroleptic
+| structure          =
-| mechanism         = D2/D3 partial agonist; 5-HT1A partial agonist; 5-HT2A antagonist
+| classes            = Antipsychotic, Neuroleptic
 }}
 [[Category:Neuroleptics]]